Obesity trials advance alongside a mounting legal fight
- VK2735 is the main story, with injectable Phase 3 trials running and oral Phase 3 planned for Q4 2026.
- Viking had $501.9 million in cash, cash equivalents, and short-term investments as of June 30, 2026.
- The company escalated its legal fight with Ligand by filing a cross-complaint in July 2026 to protect the TR-Beta license.
- VK3019 moved into human testing in June 2026, adding a second obesity pathway beyond GLP-1 and GIP.
VK2735 carries the stock
Viking is a high-risk biotech built around one big question: can VK2735 become a serious obesity drug? The injectable form is in the VANQUISH Phase 3 program, and the oral form is expected to start Phase 3 in Q4 2026. A maintenance dosing study is also underway. If the data hold up, Viking could own a valuable obesity asset in one of the largest drug markets in the world.
The bull case is that Viking is moving fast and has more than one shot on goal. VK2735 has both injectable and oral paths. VK3019, its amylin agonist program, began a Phase 1 study in June 2026. That gives Viking a possible next wave in obesity, not only a single program.
The bear case revolves around intense competition and legal risk. Ligand Pharmaceuticals is trying to terminate the TR-Beta license, which includes VK2809 for NASH and VK0214 for X-ALD. Viking filed a cross-complaint in July 2026 to protect its rights. Until the dispute is resolved, VK2809 is a legal overhang rather than a clean pipeline asset.
Cash is enough for now, but the burn rate is high. Viking reported $501.9 million of cash, cash equivalents, and short-term investments at June 30, 2026. Management says that funds operations through at least September 30, 2027, but the rising costs of Phase 3 trials mean the company will eventually need to raise more capital.
No sales yet, trial value only
Viking does not have an approved product and does not generate product revenue. Its business is to test drug candidates, raise capital, and try to turn clinical data into either an approved drug, a partnership, or a sale of rights.
That makes the model simple but risky. Cash goes out for research, trials, manufacturing, lawyers, and public company costs. Value comes in only if a program clears clinical and regulatory steps, or if a larger drug company pays to partner with Viking.
VK2735 is the main value driver. The company has also invested in manufacturing capacity with CordenPharma for active ingredient and finished supply. That helps prepare for scale, but it also raises the cost of being wrong.
The Ligand relationship matters because several assets depend on licensed technology. The ongoing dispute shows a weakness in this model: even good clinical data can lose value if the legal right to use an asset is challenged in court.
Pipeline, not products
VK2735, obesity
VK2735 is a dual GLP-1 and GIP agonist. The injectable version is in the Phase 3 VANQUISH program, and the oral tablet is expected to enter Phase 3 in Q4 2026.
VK2809, NASH
VK2809 is an oral thyroid hormone receptor beta agonist for NASH, a serious liver disease tied to fat buildup and inflammation. The Ligand license dispute now clouds its value.
VK3019, amylin agonist
VK3019 is a dual amylin and calcitonin receptor agonist, also called a DACRA. Viking started a Phase 1 study in June 2026 to test safety, tolerability, and early weight effects.
VK0214, X-ALD
VK0214 targets X-linked adrenoleukodystrophy, a rare inherited disease. Viking has positive Phase 1b results and intends to seek a partner before more studies.
VK5211, hip fracture recovery
VK5211 is a selective androgen receptor modulator for patients recovering from hip fracture surgery. Viking does not plan to push it forward alone and is seeking a partner.
One reported segment
Viking reports one operating segment for the three months ended June 30, 2026: developing therapies for metabolic and endocrine disorders. The company has no commercial revenue.
What can go wrong
VK2735 Phase 3 miss
High impact · Medium oddsThe obesity program drives most of the investment case. If VANQUISH data show weaker weight loss, worse tolerability, or safety issues, Viking would have little revenue support and fewer ways to fund itself on good terms.
Obesity competition crushes the launch
High impact · High oddsNovo Nordisk and Eli Lilly already sell major obesity drugs and have far larger sales teams, trial budgets, and supply chains. VK2735 must look meaningfully different, such as better weight loss, easier dosing, or better tolerability.
Ligand license loss
High impact · Medium oddsLigand is trying to terminate the TR-Beta license. Viking filed a cross-complaint in July 2026 to fight back. If Ligand wins, Viking could lose rights to VK2809 and possibly weaken the value of VK0214.
Cash burn outruns the runway
High impact · Medium oddsViking had $501.9 million in cash, cash equivalents, and short-term investments at June 30, 2026. It expects this runway to last through at least September 30, 2027. A slower trial or weak market could force a larger and more dilutive financing.
Manufacturing scale-up slips
Medium impact · Medium oddsObesity drugs require reliable large-scale supply. Viking has agreements with CordenPharma for VK2735 active ingredient and finished product, but it has not launched a drug before. A supply problem could hurt trials, approval prep, or a future launch.
In one breath
Does Viking Therapeutics make money today?
No. Viking is a clinical-stage biotech with no approved products and no commercial product revenue. It funds trials with cash raised from investors.
What is Viking's most important drug?
VK2735 is the key asset. It is being tested for obesity in injectable Phase 3 trials, with an oral Phase 3 program expected to start in Q4 2026.
Why does the Ligand dispute matter?
Ligand is trying to terminate a license that covers the TR-Beta program, including VK2809 for NASH. Viking filed a cross-complaint in July 2026 to defend its rights. If Viking loses, it could lose a major pipeline asset.
How long is Viking funded?
As of June 30, 2026, Viking had $501.9 million in cash, cash equivalents, and short-term investments. Management expects this will fund operations through at least September 30, 2027.
